eleni efstathiou
eleni efstathiou
Verified email at
Cited by
Cited by
Abiraterone and increased survival in metastatic prostate cancer
JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ...
New England Journal of Medicine 364 (21), 1995-2005, 2011
Abiraterone in metastatic prostate cancer without previous chemotherapy
CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ...
New England Journal of Medicine 368 (2), 138-148, 2013
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ...
The Lancet 375 (9724), 1437-1446, 2010
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade
VK Arora, E Schenkein, R Murali, SK Subudhi, J Wongvipat, MD Balbas, ...
Cell 155 (6), 1309-1322, 2013
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
J Gao, JF Ward, CA Pettaway, LZ Shi, SK Subudhi, LM Vence, H Zhao, ...
Nature medicine 23 (5), 551-555, 2017
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer
CN Sternberg, K Fizazi, F Saad, ND Shore, U De Giorgi, DF Penson, ...
New England Journal of Medicine 382 (23), 2197-2206, 2020
Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ...
European urology 77 (4), 508-547, 2020
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ...
European urology 66 (5), 815-825, 2014
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant …
CJ Logothetis, E Basch, A Molina, K Fizazi, SA North, KN Chi, RJ Jones, ...
The lancet oncology 13 (12), 1210-1217, 2012
PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3
A Salameh, AK Lee, M Cardó-Vila, DN Nunes, E Efstathiou, FI Staquicini, ...
Proceedings of the National Academy of Sciences 112 (27), 8403-8408, 2015
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer
E Efstathiou, M Titus, S Wen, A Hoang, M Karlou, R Ashe, SM Tu, ...
European urology 67 (1), 53-60, 2015
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology
JP Droz, M Aapro, L Balducci, H Boyle, T Van den Broeck, P Cathcart, ...
The lancet oncology 15 (9), e404-e414, 2014
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
JC Araujo, GC Trudel, F Saad, AJ Armstrong, YY Evan, J Bellmunt, ...
The lancet oncology 14 (13), 1307-1316, 2013
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response
CJ Ryan, S Shah, E Efstathiou, MR Smith, ME Taplin, GJ Bubley, ...
Clinical Cancer Research 17 (14), 4854-4861, 2011
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone
E Efstathiou, M Titus, D Tsavachidou, V Tzelepi, S Wen, A Hoang, ...
Journal of clinical oncology 30 (6), 637, 2012
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma
MA Dimopoulos, G Hamilos, A Zomas, D Gika, E Efstathiou, V Grigoraki, ...
The Hematology Journal 5 (2), 112-117, 2004
Androgen receptor–negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms
ZG Li, P Mathew, J Yang, MW Starbuck, AJ Zurita, J Liu, C Sikes, ...
The Journal of clinical investigation 118 (8), 2697-2710, 2008
Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients
HJ Boyle, S Alibhai, L Decoster, E Efstathiou, K Fizazi, N Mottet, S Oudard, ...
European Journal of Cancer 116, 116-136, 2019
The system can't perform the operation now. Try again later.
Articles 1–20